49 completed, 15 recruiting, 10 terminated, 8 active not recruiting. 90 Phase 2, 6 Phase 1, 3 Phase 3.
Follow Hidradenitis Suppurativa: new trials by email Literature Review of Hidradenitis Suppurativa trials Research Report on Hidradenitis Suppurativa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of SL-325 in Participants With Hidradenitis Suppurativa SL-325, Placebo - Hidradenitis Suppurativa (HS) | Phase 2 | Not yet recruiting | Shattuck Labs, Inc. | 150 | 2027-01-01 | 2026-11-13 |
| Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity Olatorepatide, Placebo - Hidradenitis Suppurativa | Phase 2 | Recruiting | Regeneron Pharmaceuticals | 300 | 2026-10-29 | 2026-11-10 |
| A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial) SPY072, Placebo, bimekizumab - Hidradenitis Suppurativa (HS) | Phase 2 | Recruiting | Spyre Therapeutics, Inc. | 150 | 2026-10-06 | 2026-11-18 |
| Botulinum Toxin Blockade of Neuronal Signals to Immune Cells as a Novel Treatment for Hidradenitis Suppurativa Botulinum Toxin A (Allergan, Inc, Irvine CA), Placebo - Hidradenitis Suppurativa (HS) | Phase 2 | Not yet recruiting | University of Massachusetts, Worcester | 40 | 2026-10-01 | 2026-09-10 |
| Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa Roflumilast 0.3% topical foam - Hidradenitis Suppurativa (HS) | Phase 2 | Recruiting | Harrison Dermatology | 10 | 2026-09-10 | 2026-10-13 |
| The Safety and Efficacy of Roflumilast Foam in HS Roflumilast 0.3% topical foam - Hidradenitis Suppurativa (HS) | Phase 2 | Recruiting | Beth Israel Deaconess Medical Center | 20 | 2026-09-01 | 2026-07-09 |
| ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa ORKA-002, Placebo - Hidradenitis Suppurativa (HS) | Phase 2 | Recruiting | Oruka Therapeutics, Inc. | 200 | 2026-08-21 | 2026-10-29 |
| A 24-Week Real-World Study of Upadacitinib in Moderate-to-Severe Hidradenitis Suppurativa Upadacitinib - Hidradenitis Suppurativa (Acne Inversa) | Phase 2 | Active not recruiting | Peking Union Medical College | 50 | 2026-07-01 | 2026-07-27 |
| A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa LAD328, Placebo - Hidradenitis Suppurativa | Phase 2 | Recruiting | Almirall, S.A. | 50 | 2026-05-13 | 2026-08-17 |
| Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Povorcitinib - Hidradenitis Suppurativa (HS) | Phase 2 | Recruiting | Incyte Corporation | 40 | 2026-02-02 | 2026-11-13 |
| A Study of Zasocitinib in Adults With Hidradenitis Suppurativa Zasocitinib (Dose A), Placebo - Hidradenitis Suppurativa | Phase 2 | Active not recruiting | Takeda | 91 | 2026-01-26 | 2026-11-04 |
| A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa NAV-240, Placebo to match NAV-240 - Hidradenitis Suppurativa (HS) | Phase 2 | Recruiting | Navigator Medicines, Inc. | 150 | 2026-01-05 | 2026-07-22 |
| A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa SAR445399, Placebo - Hidradenitis Suppurativa | Phase 2 | Recruiting | Sanofi | 144 | 2025-12-29 | 2026-10-16 |
| Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa SCT650C - Hidradenitis Suppurativa (HS) | Phase 2 | Recruiting | Sinocelltech Ltd. | 60 | 2025-12-16 | 2026-04-28 |
| A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS. Ritlecitinib, Placebo - Hidradenitis Suppurativa | Phase 2 | Active not recruiting | Pfizer | 128 | 2025-11-13 | 2026-11-10 |
| Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa Brivekimig, Placebo - Hidradenitis Suppurativa | Phase 2 | Recruiting | Sanofi | 208 | 2025-11-06 | 2026-10-14 |
| A Study of LAD191 in Adults With Hidradenitis Suppurativa LAD191, Placebo, Adalimumab - Hidradenitis Suppurativa | Phase 2 | Recruiting | Almirall, S.A. | 200 | 2025-11-05 | 2026-05-11 |
| A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa BFB759, Placebo for BFB759 - Hidradenitis Suppurativa (HS) | Phase 2 / Phase 3 | Active not recruiting | Bluefin Biomedicine, Inc. | 210 | 2025-11-03 | 2026-10-14 |
| A Study With CIT-013 in HS Patients CIT-013 high dose, CIT-013 medium dose, Placebo - Hidradenitis Suppurativa (HS) | Phase 2 | Active not recruiting | Citryll BV | 108 | 2025-10-31 | 2026-10-19 |
| A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa Topical roflumilast 0.3% foam - Hidradenitis Suppurativa | Phase 2 | Completed | Tulane University | 10 | 2025-09-25 | 2026-10-09 |
Showing 20 of 90. Sign in to see all of them.
Hidradenitis (9) · Skin Diseases (9) · Abscess (3) · Sweat Gland Diseases (3) · Dermatitis (2) · Dermatitis, Atopic (2) · Inflammation (2) · Skin Diseases, Bacterial (2) · Acne Vulgaris (1) · Alopecia Areata (1) · Autoimmune Diseases (1) · Chronic Urticaria (1) · Down Syndrome (1) · Eczema (1)
Bacterial Infections (90) · Bacterial Infections and Mycoses (90) · Skin Diseases, Infectious (90) · Infections (89) · Skin and Connective Tissue Diseases (89) · Suppuration (89) · Skin Diseases, Bacterial (88) · Sweat Gland Diseases (87) · Hidradenitis (81) · Skin Diseases (81) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Inflammation (4) · Hypersensitivity (3) · Hypersensitivity, Immediate (3)
Adalimumab (6) · Roflumilast (3) · Sodium Chloride (3) · BDB001 (2) · Gentian Violet (2) · Injections (2) · Interleukin 1 Receptor Antagonist Protein (2) · apremilast (2) · bermekimab (2) · bimekizumab (2) · guselkumab (2) · lutikizumab (2) · spesolimab (2) · upadacitinib (2) · vilobelimab (2)
Incyte Corporation (5) · AbbVie (4) · Boehringer Ingelheim (4) · Florida Academic Dermatology Centers (4) · Janssen Research & Development, LLC (4) · Sanofi (4) · Beth Israel Deaconess Medical Center (3) · InflaRx GmbH (3) · Almirall, S.A. (2) · Eli Lilly and Company (2) · Novartis Pharmaceuticals (2) · Pfizer (2) · Staidson (Beijing) Biopharmaceuticals Co., Ltd (2) · University Medical Center Groningen (2) · University of Athens (2)
United States (65) · Canada (35) · Germany (32) · Poland (24) · Spain (23) · Netherlands (20) · Australia (19) · France (16) · Greece (16) · China (10) · Bulgaria (9) · Denmark (9) · Japan (9) · Czechia (8) · Italy (8)
Baoxi Wang, Master (2) · Evangelos J Giamarellos-Bourboulis, MD, PhD (2) · Francisco A Kerdel, M.D (2) · Kathleen Butler, MD (2) · Martina Porter, MD (2) · Ajay Aggarwal (1) · Alexandra B Kimball, MD, MPH (1) · Alexandra Kimball, MD, MPH (1)
PMID 34252397, PMID 34978076, PMID 19185954, PMID 20115947, PMID 23247938, PMID 26579854, PMID 27136622, PMID 29380251, PMID 32004568, PMID 34406364, PMID 36892753, PMID 37317022, PMID 37522746, PMID 38335032, PMID 38946973, PMID 39737640, PMID 39899371, PMID 39909350, PMID 41061970, PMID 41081529, PMID 41848710
2025 (7), 2023 (3), 2018 (2), 2004 (1), 2008 (1), 2017 (1), 2019 (1), R33AR077495 (1), R61AR087105 (1)